Merck reports positive HRQoL in phase 3 KEYNOTE-024 trial of KEYTRUDA (pembrolizumab)

Merck (MSD) has reported positive health-related quality of life (HRQoL) findings from an exploratory analysis from the phase 3 KEYNOTE-024 trial investigating the use of KEYTRUDA (pembrolizumab) for the treatment of patients with metastatic non-smal …

Source: Drug Development Technology - December 9, 2016 Category: Pharmaceuticals Source Type: news